ME-143 / Lite Strategy - LARVOL DELTA

Marshall Edwards presents results from clinical trial of lead oncology drug candidate ME-143 (MEI Pharma, ASCO 2012) - P1, N=15; Study ID ME-143-001; Marshall Edwards announced results from a P1 clinical trial of its lead drug candidate ME-143 in patients with solid refractory tumors; The data were presented at the ASCO Annual Meeting in Chicago; 15 pts were enrolled in escalating dose cohorts of 2.5 mg/kg, 5 mg/kg, 10 mg/kg & 20 mg/kg; SD was observed in one pt at more than 15 weeks, which is comparable to P1 studies of phenoxodiol, the Company’s first-generation NADH oxidase inhibitor, in which SD was also the best response observed; Anticipated P2 efficacy studies of ME-143 in combination with SOC chemotherapy later this year

Anticipated new P2 trial • P1 data • Oncology

Marshall Edwards presents results from clinical trial of lead oncology drug candidate ME-143 (MEI Pharma, ASCO 2012) - P1, N=15; Study ID ME-143-001; Marshall Edwards announced results from a P1 clinical trial of its lead drug candidate ME-143 in patients with solid refractory tumors; The data were presented at the ASCO Annual Meeting in Chicago; 15 pts were enrolled in escalating dose cohorts of 2.5 mg/kg, 5 mg/kg, 10 mg/kg & 20 mg/kg; SD was observed in one pt at more than 15 weeks, which is comparable to P1 studies of phenoxodiol, the Company’s first-generation NADH oxidase inhibitor, in which SD was also the best response observed; Anticipated P2 efficacy studies of ME-143 in combination with SOC chemotherapy later this year

Anticipated new P2 trial • P1 data • Oncology

Marshall Edwards announces terms for rights offering to stockholders (PRNewswire) - Marshall Edwards announced that it has set the record date and pricing terms for its previously announced rights offering to existing stockholders; Company intends to use the net proceeds from the offering primarily to continue the clinical development of its two lead oncology drug candidates, ME-143 & ME-344

Financial update • Oncology

Study of Molecular Mechanism of the Interaction Between MEK1/2 and Trametinib with Docking and Molecular Dynamic Simulation. (PubMed, Interdiscip Sci) - "The results showed that trametinib inactivates the enzyme by bonding to a group of amino acids including Lys97/101, SER218/216, Asp208/212, and Met143/147 in MEK1/2. By bonding to the essential amino acids, trametinib inhibits the activity of the enzyme. All in all, the acquired results can be of great use in designing new inhibitors."

Journal